Novel variant in glycophorin c gene protects against ribavirin-induced anemia during chronic hepatitis C treatment.
Lin JJ, Loucks CM, Trueman JN, Drögemöller BI, Wright GEB, Yoshida EM, Ford JA, Lee SS, Kim RB, Al-Judaibi B, Schwarz UI, Ramji A, Tam E, Ross CJ, Carleton BC.
Lin JJ, et al.
Biomed Pharmacother. 2021 Nov;143:112195. doi: 10.1016/j.biopha.2021.112195. Epub 2021 Sep 22.
Biomed Pharmacother. 2021.
PMID: 34562771
Free article.
BACKGROUND: The current use of ribavirin in difficult-to-cure chronic hepatitis C patients (HCV) and patients with severe respiratory infections is constrained by the issue of ribavirin-induced hemolytic anemia that affects 30% of treated patients, requiring dosage …
BACKGROUND: The current use of ribavirin in difficult-to-cure chronic hepatitis C patients (HCV) and patients with severe resp …